Diletta Valsecchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Diletta Valsecchi has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Zambelli
Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy
10 shared publications - Claudio Zamagni
Addarii Medical Oncology IRCCS Azienda Ospedaliero‐Universitaria di Bologna Bologna Italy
10 shared publications - Daniela Castelletti
Novartis Farma SpA 26 Oncology Milan, Italy
10 shared publications - Donatella Grasso
Novartis Farma SpA 26 Oncology Milan, Italy
10 shared publications - Emanuela Romagnoli
21U.O.C. Oncologia Presidio Ospedaliero di Macerata, ASUR Marche, Macerata, Italy
10 shared publications - Fabio Puglisi
Department of Medical Oncology, CRO di Aviano, National Cancer Institute, IRCCS, 33081 Aviano, Italy; Department of Medicine, University of Udine, 33100 Udine, Italy
10 shared publications
Latest Publications
- Open Access
- 22 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (14) , 5735
Patient Journey and Unmet Needs in Hidradenitis Suppurativa: Insights from an Italian Survey
Background/Objectives: Hidradenitis suppurativa (HS), a chronic, inflammatory skin condition, severely affects quality of life. Despite advances in understanding its pathophysiology, major gaps persist in diagnosis and management. This study examined the journeys and unmet needs of Italian participants via an online survey, focusing on diagnostic delays, treatments, and quality of life for HS. Methods: Data were collected through a survey shared by the HS patient association in a dedicated Facebook group, using 45 closed-ended questions through Computer-Assisted Web Interviews. A total of 320 participants completed the survey in January 2023. Results: Participants reported consultations with approximately five clinicians before receiving a formal diagnosis, with a 10-year delay. Dissatisfaction with primary care was high (73%). Dermatologists played a central role in disease management. Only 24% of participants were on biologic therapy, despite the higher satisfaction levels compared to other treatments. HS was associated with quality-of-life impairments, particularly in psychological wellbeing (58%), daily functioning, and economic productivity. Unmet needs included better psychological support, improved access to biologics, nutritional guidance, and increased awareness of the disease among healthcare professionals. Conclusions: HS imposes considerable physical, psychological, and economic burdens. Earlier diagnosis, improved treatment strategies, and enhanced patient-centered care are essential to reducing this burden.
- 22 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (14) , 5735
Open AccessPatient Journey and Unmet Needs in Hidradenitis Suppurativa: Insights from an Italian Survey
Background/Objectives: Hidradenitis suppurativa (HS), a chronic, inflammatory skin condition, severely affects quality of life. Despite advances in understanding its pathophysiology, major gaps persist in diagnosis and management. This study examined the journeys and unmet needs of Italian participants via an online survey, focusing on diagnostic delays, treatments, and quality of life for HS. Methods: Data were collected through a survey shared by the HS patient association in a dedicated Facebook group, using 45 closed-ended questions through Computer-Assisted Web Interviews. A total of 320 participants completed the survey in January 2023. Results: Participants reported consultations with approximately five clinicians before receiving a formal diagnosis, with a 10-year delay. Dissatisfaction with primary care was high (73%). Dermatologists played a central role in disease management. Only 24% of participants were on biologic therapy, despite the higher satisfaction levels compared to other treatments. HS was associated with quality-of-life impairments, particularly in psychological wellbeing (58%), daily functioning, and economic productivity. Unmet needs included better psychological support, improved access to biologics, nutritional guidance, and increased awareness of the disease among healthcare professionals. Conclusions: HS imposes considerable physical, psychological, and economic burdens. Earlier diagnosis, improved treatment strategies, and enhanced patient-centered care are essential to reducing this burden.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data S1 from Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial
Supplementary Data of correlation analysis
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S1 from Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial
Supplementary Data of correlation analysis
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial
Breast cancer-related genes analyzed in the BioItaLEE gene panel (N=39)
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial
Breast cancer-related genes analyzed in the BioItaLEE gene panel (N=39)
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial
PFS in the ITT population and & Waterfall plot displaying sum of diameters greatest reduction versus screening (%)
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial
PFS in the ITT population and & Waterfall plot displaying sum of diameters greatest reduction versus screening (%)
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods S1 from Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods S1 from Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial